Achillion Pharmaceuticals inc (NASDAQ:ACHN) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Achillion Pharmaceuticals inc (NASDAQ:ACHN) gained 7.97 Percent and closed its previous trading session at $2.71. The stock traded with the average Volume of 1.11 Million at the end of last session.
Achillion Pharmaceuticals inc (NASDAQ:ACHN) has the Market Capitalization of 385.36 Million. The Stock has its 52-week High of $5.19 and 52-Week Low of $2.33 and it touched its 52-week high on 08/31/17 and 52-Week Low on 08/06/18
The company reported its last earnings Actual EPS of $-0.12/share. While, the analyst predicted that the company could provide an EPS of $-0.13/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.01/share which shows an Earnings Surprise of 7.7 Percent.
Sell side analysts plays vital role in buying and selling a stock where 0 analysts rated Achillion Pharmaceuticals inc (NASDAQ:ACHN) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -1.4% where SMA50 and SMA200 are -6.28% and -17.12% respectively.
The company shows its Return on Assets (ROA) value of -24.6%. The Return on Equity (ROE) value stands at -25.6%.
Achillion Pharmaceuticals inc (NASDAQ:ACHN) currently has a Weekly Volatility of 6.25% percent while its Monthly Volatility is at 5.76% percent. While talking about Performance of the Stock, Achillion Pharmaceuticals inc currently has a Weekly performance of 5.45%, monthly performance percentage is -3.56 percent, Quarterly performance is -22.13 percent, 6 months performance shows a percent value of -4.91% and Yearly Performance is -43.66 percent.
ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company’s proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.